All-trans retinoic acid
by the novel mechanism of induction of cytodifferentiation and maturation of leukemic cells5 The combination of retinoic acid and conventional cytotoxic agents has recently been reported to provide a more effective overall therapy for APL than conventional chemotherapy Unfortunately, clinical remissions in patients treated with RA alone are not Proposed explanations for the early relapses seen in these patients include the increased production of cytosolic retinoic acid binding proteins and other mechanisms by which RA may upregulate its own metabolism?-" Two recent reports implicate cellular or molecular mechanisms of resistance in human APL cells. Dubois et al'' find occasional de novo resistance in vitro and in vivo to tRA, while Miller et all3 find resistance in vitro to tRA in relapsed patients, as well as clinical resistance to 9-cis RA in some patients who achieved and maintained high plasma levels of this active retinoid isomer.
Recent studies suggest that PMWRAR-a blocks promyelocytic differentiation by a dominant negative effect on R A I 4 . I 5 or PML'6.17 signal transduction pathways. However, these studies have yielded little information on the mechanism by which RA may overcome the APL cell's block to differentiation. An in vitro model system of APL cell differentiation is provided by a cell line, NB4, derived from leukemic cells of a patient with M L . " NB4 cells show the t(15;17) karyotypic abnormality characteristic of APL, express the fusion PMLRAR-a "A, can be induced to differentiate in vitro, and provide unique reagents for the study of the aberrant structure and function of RAR-a, as well as PML." Subclones of NE34 have been selected for resistance to tRA.'9.z' However, in NB4.306, the only published resistant cell line analyzed for PML/RAR-a RNA and protein expression, Northern analysis shows expression of PMLIRAR-a RNA, while Western blot analysis with a RARa antibody directed to the C-terminal portion (F domain) subclones of NB4 that are stably resistant to both tRA and 9-cisRA. Unlike the previously reported NB4.306 retinoidresistant cells, these subclones expressed PMLIRAR-a RNA and protein, but demonstrated altered ligand binding patterns of PMLIRAR-a and differed in retinoid-induced gene expression. They were significantly less able to stimulate transcription of an RARE driven CAT-reporter gene on induction by tRA and showed altered DNA binding activity on a RARE. These data suggest that NB4 cells selected for resistance to retinoids demonstrate abnormal ligand binding to PMLIRAR-a that lead to altered transcriptional activation by retinoids.
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fails to show expression of PMWRAR-a protein." In this report, we describe NB4 subclones that are stably resistant to both tRA and 9-cis RA, a retinoid that binds to both types of RA nuclear receptors; RARs and the related RXRs?','' These resistant cell lines, in contrast to NB4.306, still express PMLRAR-a protein, recognized by both PML-and RARa specific antibodies. However, we find that ligand binding of the fusion protein in these resistant lines is variably altered from that of the parental retinoid-sensitive cells. To begin to investigate potential molecular mechanisms of resistance in these derived cell lines, we compared alterations in retinoid-induced gene expression, the ability to transcriptionally activate a known RARE, and DNA binding activity with that of NB4. We found a pattern of regulated gene expression in the RA-sensitive NB4 that is partially, but not completely, lost in resistant cells. This is consistent with altered ligand binding and a reduced, but not abolished ability of resistant cell lines to transactivate an RARE in the presence of RA, compared with NB4.
France). A single cell subclone, NB4D5 was selected and used in these experiments. This subclone reproducibly differentiates to mature granulocytic cells on treatment with RA and maintains the PML/ RAR-a fusion rearrangement by reverse transcriptase-polymerase chain reaction (RT-PCR). Additional single cell subclones of NB4D5 have retained the PMLRAR-a transcript and responsiveness to tRA. NB4 subclones were routinely grown in RPMI (GIBCO-BRL, Burlington, Ontario, Canada) plus 10% fetal calf serum (FCS) (Upstate Biotechnology Inc, Lake Placid, NY) containing penicillin, streptomycin and glutamine with pC0, of 5% at 37°C humidified air. RAresistant NB4 subclones were derived by growth of NB4D5 in the above media with IO-' to lo-' mom tRA. Stable cell lines resistant to RA became apparent after approximately 3 months of culture in tRA. Single cell subclones were isolated on methylcellulose (StemCell Technology Inc, Vancouver, BC) supplemented with IO-' moll L tRA. For the indicated experiments, HL-60 cells obtained from the American Type Culture Collection (Rockville, MD) were grown in RPMI with 20% FCS.
Cyrogenetic analysis. Cells were subcultured in RPMI medium and harvested after synchronization with thymidine after 3 days of culture. GTG banding was performed, and chromosomes were classified according to the international nomenclature (Intemational System of Cytogenetic Nomenclature, 1995). Thirteen to 16 cells were counted, and four to six karyotypes were obtained for each subclone.
Cell lines were grown in the above media in the presence of varying concentrations of retinoids. Alltrans retinoic acid (tRA) was obtained from a Sigma Chemical Company (St Louis, MO). 9-cis RA was obtained as a gift from Dr R.A. Heyman (Ligand, CA). Solutions of both retinoids were prepared as lo-' moVL in dimethyl sulfoxide (DMSO) after incubations as described. Cytospin slides were stained with Giemsa and assessed for morphology by a light microscope. Immunohistochemical staining with a PML-specific antibody was performed as previously described." Nitroblue tetrazoliam (NBT) reduction assay, with and without phorbol myristate acetate (PMA) stimulation to augment the induction of granulocytic differentiation, was performed as previously reported." Analysis of cell surface antigens was performed on a Faxflo Cytometer (Becton Dickinson, Bedford, MA). Control antibodies and antibodies to CD1 Ib (MO-I) and C D l l c were used as described." Growth inhibition by RA was determined by culture of 25,000 cells per well in the above medium with the indicated doses of RA for 6 days. Retinoid was replenished after 3 days, as we have found retinoid levels in cell culture media to decrease with time, either by metabolism in the cells or by chemical isomerization (unpublished) . Triplicate samples were counted on days 3 and 6 by hemocytometer. Trypan blue positive cells never exceeded 10% and were excluded from the count.
Analysis of gene expression. Cells were washed with fresh media lacking FCS or retinoid and extracted with guanidine isothiocyanate. Total cellular RNA was prepared as previously described?' and electrophoresed on a 1 % formaldehyde agarose gel and blotted onto MSI-Nitropure nitrocellulose (MSI, Westboro. MA) or Zeta probe (Bio-Rad Laboratories, Mississauga, Ontario, Canada) transfer membranes. The obtained filters were hybridized to DNA probes labeled by random priming (Pharmacia Biotech, Baie d'Urfe, Quebec, Canada). Hybridizations and autoradiography were performed as previously described." The radiolabelled probes were isolated from plasmids containing: a 0.6-kb Pst I fragment of human RAR-CY cDNA,*' a 1.8-kb EcoRI cut human RXR-CY cDNA," and a fulllength human myeloblastin cDNA." A 0.8-kb N-terminal cDNA probe for Type 11 transglutaminase (TGase 11) was prepared by RT-PCR. Expression of RAR-CY and PMLRAR-a was also determined by RT-PCR. This was performed on extracted RNA as previously described.2x
Protein isolation und Western analysis. Total cellular protein was isolated according to Dermime et al'" from 3 x 10' cells suspended in SO uL buffer containing: 100 mmol/L NaCI, IO mmol/L Tris-HCL (pH 7.6), 1 mmol/L EDTA (pH KO), 1 pg/mL aprotinin, and 100 pg/mL pbenylmethylsulfonyl fluoride (PMSF). Cells were lysed by adding 50 pL buffer containing: 100 mmol/L Tris-HCL (pH 6.8), 200 mmol/L dithiothreitol (DTT), 4% sodium dodecyl sulfate (SDS), 0.2% bromphenol blue, and 20% glycerol, followed by boiling for I O minutes and sonication. Aliquots were electrophoresed in 10% SDS acrylamide gel and transferred to nitrocellulose membranes (Bio-Rad Laboratories, Mississauga, Ontario, Canada). Membranes were blocked with 5% skim milk in phosphate-buffered saline (PBS) and hybridized overnight with antibody. An antibody to the RAR-a F domain was kindly provided by P. Chambon (Strasbourg, France) and used at a 1:2,000 dilution. An affinity-purified antibody to the amino terminal domain of PML" was a gift from R.M. Evans (La J o b , CA) and used at a dilution of 1500. After washing in PBS, membranes were incubated with a secondary antibody (antirabbit Ig horseradish peroxidase, Amersham Life Science, Arlington Heights, IL) for 1 hour and developed with the ECL system (Amersham) or using Protein A radiolabeled iodine (Amersham).
Nuclear extracts were prepared from 1 to 5 X lo8 cells and incubated for 18 hours at 4°C with I O nmol/L ['HI-tRA (50.7 C i h m o l ; DuPont-NEN, Boston, MA) as previously described.*',"' The extracts were fractionated at 4°C by high performance liquid chromatography (HPLC) using a Superose 6 HR 10/30 size exclusion column (Pharmacia, Uppsala, Sweden). The flow rate was 0.4 mllminute. Fractions of 0.4 mL were collected and radioactivity in each fraction was determined using a scintillation counter. The HPLC system was calibrated using a series of molecular-weight markers including: blue dextran MW 2,000,000; thyroglobulin, MW 669,000; P-amylase, MW 200,000; bovine albumin. MW 66,000: ovalbumin, MW 45,000.
NB4 and the resistant cell lines were transiently transfected with a PREtkCAT (a generous gift from H. Sucov, La Jolla, CA) reporter gene and a CMVPGal plasmid (Clonetech Laboratories, Palo Alto, CA) as an internal control. For transfections, cells were grown in standard media to a density of 0.6 to 0.9 x 10' cells per mL, rinsed once with Opti-MEM (GIBCO-BRL) without serum, and IO' cells were resuspended in 0.5 mL of Opti-MEM at room temperature in electroporation cuvettes. A total of I O ug of each plasmid were added. Electroporation was performed using a Gene-Pulser (BioRad) apparatus at 350 V and 960 ~L F capacity. After electroporation, cells were resuspended in 5 mL of standard medium with or without retinoids. Cells were harvested 48 hours after transfection and the PGal activity assessed according to Sambrook et ai."
The CAT activity was measured using a modified protocol of the organic diffusion method." Cell extracts were standardized to PGal activity in a total volume of 50 p L and incubated at 37°C with 200 pL of 1.25 mmol/L cold chloramphenicol (ICN, Costa Mesa, CA.) dissolved in 100 mmol/L Tris-CI (pH 7.8) and 0.25 pCi of 'H-labeled acetyl coenzyme A (NEN, Streetsville, ON) and 22.5 p L of 0.1 mmol/L cold acetyl CoA (Pharmacia). The reaction was allowed to proceed for 16 hours, after which the organic phase was extracted with Ready Organic Scintillation Cocktail (Beckman, Mississauga, Ontario, Canada). The radioactivity of 200 pL of the organic phase was counted on a p-Counter (Beckman).
Cells were treated with or without retinoids as indicated and nuclear extracts prepared according to the method of Andrews and 
Gel retardution assays.
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From allowed to incubate for 15 minutes on ice. Subsequently, 1 ng of 32-P-radiolabeled oligonucleotide P-DR5 (S-TAAAAGGTCACC-GAAAGGTCACTCGCAT-3'), was added with or without a 200-fold excess of cold competitor oligonucleotide. After a 30-minute binding reaction at room temperature, the mixture was electrophoresed at 200 V in a 5% polyacrylamide gel in low-ionic strength conditions of 0.5 X Tris-borate (TBE) buffer. Anti-RAR-a antibody (described above) and anti-RXR-a antibodies, generous gifts from R.M. Evans (La Jolla, CA) and T. Antakly (Montrbal, Quebec, Canada), were allowed to incubate with the complexes 15 minutes on ice before electrophoresis.
RESULTS

Development and phenotype of RA-resistant subclones.
For the development of RA-resistant subclones of NB4 and for the comparisons in this report, a single cell subclone, NB4D5, was derived from the parental NB4 line obtained from M. Lanotte. " This subclone reproducibly differentiates to mature granulocytic cells on treatment with tRA and maintains the PMLRAR-a fusion rearrangement by RT-PCR. Additional single cell subclones of NB4D5 have retained the PMLRAR-a transcript and responsiveness to RA. RAresistant NB4 subclones were derived by growth of NB4D5 in media with lo-' to lo-' m o m tRA. Stable cell lines resistant to tRA became apparent after 3 months in the presence of tRA. The resultant cell lines were highly resistant to the growth inhibitory and differentiation effects of both tRA and 9-cis RA. To establish if these cell lines were stably resistant to the granulocytic differentiation induced and well documented in NB4 cells by tRA, the resistant cell lines were allowed to grow in media without selection for 1 month followed by treatment with tRA. Figure 1 illustrates the growth and survival of 10 resistant cell lines in the presence of m o m tRA, as represented by the cell number as a percentage of untreated controls. At 6 days in culture, NB4 cells were 90% growth inhibited, whereas the resistant cell lines show no significant decrease in growth. Although we cannot fully rule out a growth stimulatory effect of RA in some resistant cell lines, the variations in growth rates among the resistant clones are small compared with the 90% inhibition of NB4 sensitive cells, and repeat experiments with several of the cell lines do not consistently show an increased growth rate with retinoid treatment. Staining and light microscopic examination of fixed cytospun samples of each cell line showed no evidence of morphologic differentiation (data not shown). To examine whether these RA-resistant NB4 cell lines were truly undifferentiated, we performed a functional analysis testing NBT reduction and the expression of CD1 l b and CDI IC surface antigens in the presence of lo-' molL of both retinoids in three of the resistant cell lines. Table 1 shows that after 6 days of exposure to either retinoid, NBT reduction is induced in NB4 cells, particularly when stimulated by PMA, in a dose-dependent fashion. However, even at m o m of either retinoid, no NBT induction is observed in NB4R4 cells. CD1 l b and CDl IC, previously reported as markers of differentiation of NB4 cells by RAI8 (Table 2 ) are expressed at m o m of either retinoid in NB4, but show minimal expression in either clones R4 or MR2. However, CDl IC is expressed to some degree in MR6 without retinoid treatment and is modestly induced on treatment. Thus, we have cell lines independently derived by culture in the presence of RA that show resistance to the growth inhibitory and differentiation inducing effects of tRA or 9-cis RA. These resistant clones have retained RA-resistance after 6 months in culture without retinoids (data not shown).
To search for molecular differences between sensitive and resistant cells, we examined whether the development of retinoid-resistance was associated with consistent cytogenetic changes. The NB4D5 retinoid-sensitive subclone presents a very similar karyotype to that initially reported for NB4." The cell line was hypertriploid (77-78 chromosomes) and presented the following structural abnormalities: dup(8)(?q13q22); add( 1 l)(q25); t(12;?12)(ql l;q13); t(l5; 17)(q22,q21); der(l5)add(l5)(pll) t(15; 17)(q22;q21); add(19)(q13). Various marker chromosomes were also observed. The derived resistant clones were also near-triploid (64-80 chromosomes). They presented the above abnormalities, along with others. R4 (64-78 chromosomes) had an additional add(l4)(pll) and an add (15) Retinoid receptor expression in RA-resistant NB4 subclones. We then examined the resistant clones for induced changes in the expression of the wild-type or fused RAR-a and PML genes. Northern analysis (on two representative resistant lines, Fig 2A) and RT-PCR (1 1 resistant lines, Fig  2B) for the PMLJRAR-a fusion mRNA was performed on the resistant and sensitive cell lines by previously reported techniques.28 Figure 2A shows that both the wild-type RARa and the fusion PMURAR-CY RNA species are expressed without change in two resistant lines. In Fig 2B, all resistant cell lines generated identical bands to NB4D5, indicating that no rearrangement or deletions near the breakpoint had occurred during the generation of resistance. As a control, Fig 2B also includes amplified cDNA from a patient with APL cells expressing the variant b~r 2~~ breakpoint. Since an RA resistant NB4 subclone has been reported to express PMLIRAR-a mRNA, but no PMLRAR-a protein, we examined protein expression in two resistant clones with both RAR-a and PML-specific antibodies. Figure 3A [t( 13; 13)(qlO;qlO)].
For Figure 3A , but not Fig 3B, suggests that the PMLJ RAR-a protein is decreased in expression in the resistant cell lines when compared with NB4. Additional experiments, using nuclear extracts and the more quantitative detection system of Protein A radiolabeled with iodine followed by densitometry, failed to show a consistent change in the level of protein expression. PMURAR-CY protein per cell showed no more than a two-fold difference (by densitometric scanning of the PIkKk4R-a protein bands in lanes containing protein from equal numbers of cells: NB4,7.3 arbitrary units; 
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R4, 9.5 units; MR2, 13 units or a significant decrease in the ratio of the fusion protein to wild-type RAR-a (ratio of upper bands to lower wild-type band: NB4, 18.1; R4, 11.2; MR2, 16.8). Although no wild-type PML expression is observed in HL-60, this antibody has been shown to detect PML expressed in transfected cells.I6 Similarly, we suspect that wildtype PML expression is too low, or in too many isoforms, in the APL cells whether sensitive or resistant for detection. This PML antibody was also used to examine PMURARa expression in three resistant lines (R4, MR2, MR6) by immunohistochemistry. As we have previously reported for the R4 resistant line,'6 the microparticulate pattem of staining characteristic of APL cells was seen in all clones (data not shown). However, the reorganization of PMURAR-a and PML to a wild-type pattem that occurs in NB4 after RA treatment does not occur in the resistant cells'6 (and data not shown).
Retinoid binding activity of the wild-type and rearranged RAR-a in RA-resistant NB4 subclones. Because subclones of NB4 that continued to express PMURAR-a protein were highly resistant to the differentiation and growth inhibitory effects of RA, we asked whether the ligand-binding properties of the wild type or rearranged proteins might be altered. Expression of cell surface markers for granulocytic differentiation in RA-sensitive (NB4D5) and three resistant cell lines (R4, MR2, and MR6). Cells were cultured for 7 days with mol/L of either retinoid or without (Control) as indicated. Expression of cell surface antigens was determined by indirect immunofluorescene staining of cell suspensions with the appropriate antibody. The numbers shown represent the percent of cells expressing these surface markers.
beled tRA to define the specificity of binding. As previously shown:' the HPLC profile of the nuclear extracts prepared from NB4 cells showed three main peaks with specific ['HItRA binding activity eluting with retention times of 34. 41, and 44 minutes (see Fig 4) . As in previous reports, these correspond to molecular weights of approximately 670,000 (the previously described macromolecular complexes formed by the interaction of PMURAR-a with itself a n d or other nuclear proteins's.3'~"), I 10.000 (monomeric PML/ RAR-a protein), and 50,000 (endogenous RAR-a). Peaks eluting with retention times of 21, 57, and 60 minutes were not eliminated by excess unlabeled tRA. The peak at 21 minutes coincides with the void volume of the column. The partial competition of this peak by unlabeled RA may result from nonspecific binding to extremely high MW components in the void However. it might also indicate the presence of very high MW complexes of PMURAR-a or RAR-a in the resistant cell lines. The HPLC profiles of 
(C).
Cell extracts were subjected t o HPLC analysis using a Superose 6 HR 10I30 size exclusion column. Arrows indicate the elution times of a series of specific molecular weight markers (blue dextran MW 2,000,000; thyroglobin, MW 669,000; pamylase, MW 200,000; bovine albumin, MW 66,000; ovalbumin, MW 45.000). measured by AZm. tRA 10-6 M 9cisRA 10-6 M RXR-a was not regulated by either retinoid (Fig 6A) . In NB4, expression of the serine protease myeloblastin (MBN) was induced by 24 hours. peaked at 48 hours, and returned to baseline level by 6 days with both retinoids (see Fig 5) .
We were interested to see if retinoid-regulated gene expression was also lost in the resistant cells. In contrast to the loss of RXR-a regulation. IO '' mol/L of either retinoid strongly induced MBN expression in R4 and MR2 (Fig 6B) . While, as previously reported," the induction of MBN expression is transient in the parental NB4 cells, the upregulation in R4 and MR2 persists after 4 to 6 days of retinoid treatment ( Fig  6B and data not shown) . Further, treatment with lower doses of retinoid showed a similar dose-response of MBN expression in both sensitive and resistant clones (data not shown). We then examined expression of another gene, Type I1 transglutaminase (TGase), that has been reported to be induced by retinoids in myeloid cells induced to As shown in Fig 6C. there is a dramatic induction by retinoids in NB4 cells. but not in the resistant R4 or MR2 cells.
Ahilic of sensitive versus resistant cell lines to trrtnsnctiwite mid hirid to N RARE. To determine whether the resistant cell lines are altered in their ability to support the transcription of a retinoic acid-responsive gene, we performed transient transfections using a tk-CAT reporter driven by the RARE of the RAR-0 promoter (ORE). This DR5 element binds and is activated by RAR-a/RXR-a heterodimers.'"'.'" As shown in Fig 7. NB4 cells treated with IO-" mol/L tRA showed a 96-fold increase in CAT activity over unstimulated cells. However, the CAT induction by tRA in the three resistant cell lines examined was greatly reduced, indicating a loss of transactivation ability on a strong RARE. Transactivation by 9-cis RA was also lower in the resistant lines (data not shown).
We then investigated whether the ability to bind DNA of the endogenous RAR-a and RXR-a receptors differed between the resistant cells and NB4. A gel mobility shift experiment used an oligonucleotide corresponding to a RARE-02 (DR5) as a probe and nuclear extracts of both sensitive and resistant cell lines grown in the presence or absence of retinoid. As shown in Fig XA. nuclear extracts prepared from untreated NB4 cells produced multiple shifted bands. all of which were removed by a 200-fold molar excess of unlabeled homogenous RARE (Fig 8A. lane I ) . The addition of RAR-a and RXR-a antibodies decreased one major band (Fig SA, lanes 3 and 4, indicated by number 11) and induced supershifted higher bands (seen in lanes 5 and 6). The binding pattern of nuclear extracts from NB4 cells treated with IO-" mol/L tRA or 9-cis RA differed from the controls. At least two bands (labeled I and 11) are significantly decreased in intensity on treatment with retinoid ( Fig   8A, lanes 7 to 14) . These diminished bands represent diminished binding to DNA of RAR-a and/or PMIJRAR-a as heterodimers with RXR-a, as the supershifted bands produced by either antibody to RAR-a (Fig 8A. lanes IO and  14) or RXR-a (Fig 8A. lanes 9 and 13) were also diminished.
In contrast, the NB4R4 nuclear extracts (Fig XR and C) show the same binding pattern to DRS as NB4 controls with no decrease in the intensity of the shifted bands in cells treated with either retinoid (Fig 8B, lanes 6 to 13) . The supershifted bands seen in the presence of RAR-a and RXR-a specific antibodies are also unchanged in NB4R4 nuclear extracts.
This indicates a loss of RA regulation of the DNA binding activity in the resistant cell line.
DISCUSSION
The derivation and study of retinoid-resistant subclones has led to insights into the molecular mechanisms of response to retinoids in RA-inducible embryonal carcinoma and leukemic cell lines.."." We and others have applied this 
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1! strategy to APL, which provides the unique model of a malignancy associated both with expression of a RAR fused to a novel gene and a dramatic response in vitro and in vivo to treatment with a RAR ligand. In NB4.306, the only published resistant cell line analyzed for protein expression, Western blot analysis with an RAR-a antibody directed to the ligand binding domain fails to show expression of PMWRAR-a protein.*' This is consistent with previous studies showing that retinoid-resistant subclones of other cell lines have abnormalities of structure and expression of R A R S .~'~ Evidence from the present study shows the importance of examination of independently isolated retinoid-resistant clones and suggests the existence of multiple molecular mechanisms leading to retinoid resistance. In three newly-derived resistant NB4 subclones, PMLRAR-a protein is expressed and recognized by both PML-and RARa-specific antibodies, including the same RAR-a antibody that does not detect PMLRAR-a protein in NB4.306. However, our ligand binding data suggest abnormalities in the PMWRAR-a fusion protein that are not inconsistent with the findings in NB4.306. As previously reported, we find that PMWRARa binds ligand predominantly as high MW complexes in NB4 celk3' The binding of tRA to the PMLRAR-a proteins of the resistant clones in this study is altered from the parental, RA-sensitive NB4 cells, with two clones exhibiting a changed pattern of high MW PMLRAR-a complexes and dominant negative inhibitor of transcription induced by the wild-type RAR-a, while pharmacologic doses of RA relieve this inhibiti~n.'~.''.~" If binding of PMWRAR-a to RA in NB4 cells induces a conformational change that allows renewed RAR signaling, alterations in its conformation or ability to bind ligand, as suggested by our data, could lead to retinoid resistance. The continued presence of such a protein in NB4.306, as in the resistant lines described here, would be consistent with the phenotype of a persistent block to differentiation, no longer reversible by retinoids.
We began to study the nature of resistance in these clones in several ways. Our cytogenetic analysis confirmed the karyotypic complexity and instability of NB4 reported by Lanotte et al." Clone-specific abnormalities were observed in the resistant cells, with different regions of chromosome 15 [t(3;15) , add(15)(p13), and ider(l5)] involved in each cell line. These clonal chromosomal anomalies accompany the acquisition of resistance and may be involved in its mechaFor personal use only. on October 22, 2017 . by guest www.bloodjournal.org From nism, or only be present as markers of clonal evolution.
The involvement of different structural abnormalities in each clone may be an argument for the latter.
To determine the stability of RA-resistance, we continuously grew cells in media not supplemented by retinoids for 6 months. After this time, the cells remained completely resistant to the effects of RA on growth, morphology, and surface markers of differentiation. Further, although the 9-cis isomer of RA activates an additional family of retinoid receptors2'.22 and has been reported to induce differentiation of HL-60 cells that are resistant to the all-trans i~o m e r ,~' it similarly failed to induce any evidence of differentiation.
Although these cell lines are highly resistant to the induction of differentiation by retinoids, not all functions of the remaining wild-type retinoid receptor proteins in the cells are blocked. We compared the NB4R4 clone with the parental NB4 cells for alterations in retinoid-induced gene expression. In NB4, we observed downregulation of RXR-a expression by two retinoids within 6 hours, and a prominent induction of both TGase I1 RNA and CD 1 1 b protein expression within several days (Fig 6 and Table 2 ). Although no differences were found in baseline expression of these genes in NB4R4, regulation of RXR-a, TGase 11, and CDl l b expression was lost. Although CDl I C expression was slightly induced in MR6, we believe that this is consistent with both the inhibition of some, but not all, retinoid-induced gene expression in the resistant clones, as well as our ligand binding data showing differences among the clones. Similarly, the reorganization of PML in the nucleus of NB4 by RA does not occur after treatment with either retinoid in three tested resistant lines. These data, coupled with the lack of any effect on growth or differentiation markers, suggests a global loss of retinoid response, perhaps via an upregulated metabolism (as seen in vivo") or a block of retinoid receptor transcriptional activation. However, the induction of MBN expression by both retinoids in NB4R4, even at a concentration (IO-' mol/L) that is dose-limiting in NB4 (W.M., unpublished), demonstrates that retinoids can attain effective concentrations and that some retinoid receptors remain functional and some retinoid-response pathways remain inducible in this resistant cell line. This conclusion is further supported by recent results showing that RA induces another cell surface marker, CD 18, in the differentiation-resistant NB4.306 cells?x The induction of MBN also suggests that MBN expression is proximal to (or even independent of) the block to differentiation, while regulation of other genes, including CDI l b and RXR-a, may be in the specific retinoid pathway or pathways that are required for differentiation.
The results of the transcriptional and DNA binding studies presented above support a partial loss of retinoid-induced gene expression. Using one RARE known to enhance transcription of several retinoid-responsive genes, we found that RA induced transcription less well in each of three resistant lines. Nuclear extracts from untreated NB4 and resistant clones did not differ in their binding to an oligonucleotide containing this RARE, supporting the evidence of Northern and Western analyses that the baseline expression of both wild-type and rearranged retinoid receptors is unchanged. Gel shift experiments show one retarded band (lanes 3 and 4, Fig 8A) that is supershifted by RXR-a or RAR-a antibody. In retinoid treated NB4 cells, this band is lost, along with the bands that appeared in lanes 5 and 6 with antibodies to RAR-a and RXR-a. This implies that heterodimers of RAR-a and/or PMLIRAR-a with RXR-a are lost with retinoid treatment and is consistent with the loss of RXR-a shown by Northern blotting. Although increased DNA binding affinity to a response element in the presence of ligand has been observed for some nuclear receptors, previous reports have shown that human RARs bind RAREs equally well irrespective of the presence of RA in the medium.'5,'q Indeed, the efficiency of binding to the RARE in cells transfected with PMURAR-(U is not altered by either tRA or 9-cisRA." Our data is consistent with this literature and suggests that PMLIRAR-a may be removed from the complex by retinoid treatment. Confirmation with an anti-PML antibody that reliably produces supershifted bands would be desirable. The lack of effect of retinoids on DNA binding in the resistant NB4R4 cells (Fig 8B) is consistent with the lack of regulation of RXR-a seen on the Northern blots. Whether the downregulation of heterodimers containing RXR is essential to the differentiation of these cells is suggested. but not proven by these experiments.
Although early studies of clinical resistance in APL suggested in vivo resistance with maintained in vitro sensitivity:,"' recent work by the same groups reported clinically resistant patients whose leukemic cells were also highly resistant in vitro.'2,13 The failure of several APL patients to respond despite maintained high plasma levels of 9-cisRA further supports nonphmacological mechanisms of cellular resistance." These data suggesting multiple mechanisms of resistance in vivo are very consistent with our finding of retinoid-resistant NB4 subclones whose expression of PML/ RAR-a protein differs from that of sensitive NB4 and from the previously reported NB4.306 cells.
